NASDAQ, TSX: NVCN
VANCOUVER, March 21, 2018 /PRNewswire/ - Neovasc, Inc.
("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the
development of minimally invasive transcatheter mitral valve
replacement technologies, today announced that it will report
financial results for the year ended December 31, 2017 and host a conference call and
webcast at 4:30pm Eastern Time on
Wednesday, March 28, 2018.
Conference Call & Webcast
Wednesday, March 28th @ 4:30pm Eastern Time
|
Domestic:
|
800-281-7973
|
|
International:
|
323-794-2093
|
|
Passcode:
|
4395026
|
|
Webcast:
|
http://public.viavid.com/index.php?id=128910
|
|
|
|
Replays available
through April 10:
|
|
|
Domestic:
|
844-512-2921
|
|
International:
|
412-317-6671
|
|
Conference
ID:
|
4395026
|
About Neovasc Inc.
Neovasc is a specialty medical
device company that develops, manufactures and markets products for
the rapidly growing cardiovascular marketplace. Its products
include the Neovasc Reducer™, for the treatment of refractory
angina, which is not currently available in the United States and has been available in
Europe since 2015, and the Tiara™,
for the transcatheter treatment of mitral valve disease, which is
currently under clinical investigation in the United States, Canada and Europe. For more information,
visit: www.neovasc.com.
SOURCE Neovasc Inc.